Tuesday, June 17
9.00-11.00  Blue Hall

> Welcome and introduction
S. Julius (Ann Arbor, MI, USA)

> The high-risk hypertensive patient and the promise of VALUE
S.E. Kjeldsen (Oslo, Norway)

> The best of both worlds? Rationale and place for ARBs-HCTZ combinations in managing hypertension
B. Williams (Leicester, UK)

> Interaction between angiotensin and sympathetic overactivity in hypertension: an emerging therapeutic target for angiotensin receptor blockade
S. Julius (Ann Arbor, MI, USA)

> Renal implications of angiotensin receptor blockade in patients with concomitant cardiovascular disease
M. Volpe (Rome, Italy)

> General discussion and concluding remarks